Melane Sampson, Author at BioTuesdays

Executive Moves

Tonix appoints Gary Ainsworth as VP of market access

Tonix Pharmaceuticals (NASDAQ:TNXP) has announced the appointment of Gary Ainsworth as vice president of market access, effective immediately. Mr. Ainsworth brings extensive pharmaceutical and healthcare consultancy...

January 8, 2025

Developments

MediPharm expands Brazilian presence through agreement with Teuto

MediPharm Labs (TSX:LABS; OTCQX:MEDIF) has announced an agreement with Laboratório Teuto to expand its reach into the Brazilian medical cannabis market. The company states that it has been working closely with Teuto on...

January 8, 2025

Developments

FDA clears Solid’s IND application for SGT-212 in FA

Solid Biosciences (NASDAQ:SLBD) announced that the FDA has cleared its IND application for SGT-212, a first-in-industry dual-route of administration gene therapy designed to treat the neurologic and cardiac...

January 8, 2025

Developments

CytoMed and SunAct sign agreement for solid tumor treatment trial in India

CytoMed Therapeutics (NASDAQ:GDTC) has announced the signing of a five-year business and research collaboration agreement with the SunAct Cancer Institute to investigate the efficacy, safety, tolerability, and potency...

January 7, 2025

Developments

OraSure’s HIV Self-Test approved for adolescents

OraSure Technologies (NASDAQ:OSUR) has announced that the approved age range for its OraQuick HIV Self-Test has been expanded to include individuals aged 14 and older. The company cites data from the Centers for Disease...

January 7, 2025

Feature

IMUNON harmonizing life’s blueprint with immune system through DNA-based therapies

IMUNON (NASDAQ:IMNN) is advancing a distinctive approach to treating of some of the world’s most challenging diseases, leveraging a portfolio of proprietary immunology and DNA-based platforms that harness the body’s...

January 7, 2025

Developments

Portage relaunches independent subsidiary with Peter Molloy as CEO

Portage Biotech (NASDAQ:PRTG) has announced the relaunch of its wholly-owned adenosine subsidiary, Cyncado Therapeutics, as an independently managed company headed by Peter Molloy as CEO. The company reports that...

January 6, 2025

Developments

Santhera inks exclusive distribution deal with Clinigen for AGAMREE in DMD

Santhera Pharmaceuticals (SIX:SANN) and closely held Clinigen Group have announced the signing of a supply and distribution agreement that will make AGAMREE accessible to patients with Duchene muscular dystrophy (DMD)...

January 6, 2025

Developments

Clearmind granted patent for binge behavior treatment in Macau

Clearmind Medicine (NASDAQ:CMND; FSE:CWY0) has announced that its proprietary MEAI-based binge behavior regulator program has received patent approval from the Macau International Intellectual Property Office, a special...

January 3, 2025

Developments

Eton acquires rare disease product Galzin

Eton Pharmaceuticals (NASDAQ:ETON) has announced the acquisition of Galzin, a rare disease product used in the treatment of Wilson disease. The company reports that Galzin, an FDA-approved zinc acetate, is utilized as a...

January 3, 2025

Author - Melane Sampson

Tonix appoints Gary Ainsworth as VP of market access

MediPharm expands Brazilian presence through agreement with Teuto

FDA clears Solid’s IND application for SGT-212 in FA

CytoMed and SunAct sign agreement for solid tumor treatment trial in India

OraSure’s HIV Self-Test approved for adolescents

IMUNON harmonizing life’s blueprint with immune system through DNA-based therapies

Portage relaunches independent subsidiary with Peter Molloy as CEO

Santhera inks exclusive distribution deal with Clinigen for AGAMREE in DMD

Clearmind granted patent for binge behavior treatment in Macau

Eton acquires rare disease product Galzin

General

More